Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3009 - Cetuximab in combination with methotrexate (MTX) as first-line treatment in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN), a phase Ib – randomized phase II study versus single agent MTX.

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Janneke Ham

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

J. Ham1, E. Meerten2, E. Fiets3, F. Jeurissen Mc Haaglanden4, M. Slingerland5, W.T.A. van der Graaf6, C.M.L. van Herpen1, L.V. Beerepoot7

Author affiliations

  • 1 Medical Oncology, Radboud University Medical Centre Nijmegen, 6500 HB - Nijmegen/NL
  • 2 Medical Oncology, Erasmus Cancer Institute, 3075 EA - Rotterdam/NL
  • 3 Medical Oncology, Medical Center Leeuwarden, 8901 BR - Leeuwarden/NL
  • 4 Internal Medicine, Medisch Centrum Haaglanden, locatie Westeinde, 2512 - Den Haag/NL
  • 5 Medical Oncology, Leiden University Medical Center (LUMC), 2300 RC - Leiden/NL
  • 6 Division Of Clinical Studies, Royal Marsden Hospital Institute of Cancer Research, SM2 5NG - Sutton/GB
  • 7 Internal Medicine, St. Elisabeth Tweesteden Hospital, 5000 LC - Tilburg/NL
More

Resources

Abstract 3009

Background

First-line palliative treatment in R/M SCCHN consists of the combination of cetuximab with cisplatin and 5-FU with a median progression free survival (PFS) and overall survival (OS) of 5.5 and 10.1 months, respectively, at the expense of substantial toxicity. Single agent MTX has minimal side effects, but response rate, gain in PFS and OS are limited. We hypothesized that adding cetuximab to MTX could improve PFS without adding major toxicities. Because this combination had not been tested before, we first performed a phase Ib study followed by a randomized phase II study.

Methods

In the phase Ib study, patients (pts) with previously untreated R/M SCCHN were treated with weekly MTX 40 mg/m2 and cetuximab 250 mg/m2, after a loading dose of cetuximab 400 mg/m2. The primary objectives of the phase Ib study were feasibility and safety of the combination of cetuximab and MTX. In the phase II study pts were randomized to either MTX or the combination (1:2). The primary objective of the phase II study was to detect an increase in median PFS from 3 to 5 months with combination vs single agent MTX. Secondary endpoints were toxicity and OS.

Results

Six pts were included in the phase Ib study. No dose limiting toxicities were observed, median PFS was 24.4 weeks (range 7.1-55.0). In the phase II study 45 pts were included; 15 pts received MTX (73% male, median age 64 years (range 50-77)) and 30 pts cetuximab and MTX (77% male, median age 69 years (range 46-80)). In the phase II study median PFS was significantly different: 8.0 weeks (range 3.0-39.0) in the MTX arm and 17.0 weeks (range 3.9-76.6+) in the combination arm (p=.009). Nine pts in the combination arm experienced a serious adverse event (SAE), 3 were possible treatment-related (pneumonia, pneumonitis and hypersensitivity reaction) compared with 5 pts with an SAE in the MTX group, all unrelated. OS and detailed toxicity results will be presented later.

Conclusions

The combination of cetuximab and MTX in pts with R/M SCCHN is feasible. This randomised phase II study met its primary endpoint: a significantly longer PFS in the cetuximab and MTX combination arm, while toxicity was acceptable.

Clinical trial identification

NCT02054442.

Legal entity responsible for the study

Carla M.L. van Herpen.

Funding

Merckgroup.

Editorial Acknowledgement

Disclosure

E. Meerten: Advisory board: Merck. C.M.L. van Herpen: Corporate-sponsored research: AstraZeneca, BMS, MSD, Merck. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.